Inoue and coworkers demonstrated that canagliflozin (100 mg/day) significantly improved LFT levels (AST, ALT, and GGT) in T2DM patients with NAFLD (Inoue et al., 2019[40]). The gene discussed is GPT; the disease is type 2 diabetes mellitus.